A Web-mediated follow-up application (Moovcare™) improves advanced lung cancer survival, according to a French multicenter randomized phase III study. Researchers analyzed the association and evolution of self-reported clinical symptoms over time. The median overall survival of patients who used the application was 19 months, compared to 12 months for those who received standard follow-up care. Patient quality of life was also better among patients who used the application. The study was featured in a press briefing June 6, 2016 and presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7) in Chicago, Illinois. “Through personalized follow-up using this convenient and simple online application, we can detect complications and signs of relapse and offer appropriate care earlier,” said lead study author Dr. Fabrice Denis, M.D., Ph.D., a researcher at the Institut Inter-regional de Cancérologie Jean Bernard in Le Mans, France. “This approach introduces a new era of follow-up in which patients can give and receive continuous feedback between visits to their oncologist.” After completing initial chemotherapy, radiation therapy, or surgery, 133 patients with stage III/IV lung cancer were randomly assigned to Web-mediated follow-up or standard follow-up. The standard follow-up included doctor visits and CT scans every 3-6 months (or more often at the researcher’s discretion). Patients in the Web-application group had the same schedule of planned doctor visits, but three times fewer scheduled scans. They used the Web application to self-assess symptoms weekly. Caregivers could also enter data on behalf of the patients. The application analyzed twelve symptoms and reported results to the oncologist.
Login Or Register To Read Full Story